It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take ...

Wonder drugs’ like Ozempic, hailed by celebrities and some medics as a cure for an ever-mounting list of conditions, most notably obesity and diabetes, have started to appear in darker headlines ...

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

In a fresh appearance on CNBC’s Squawk on the Street, Jim Cramer cautioned viewers to not be caught up by the energy that’s ...